摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 4-<2-(4-phenylsulfonylamino)ethylsulfinyl>phenoxyacetate | 141267-11-0

中文名称
——
中文别名
——
英文名称
ethyl 4-<2-(4-phenylsulfonylamino)ethylsulfinyl>phenoxyacetate
英文别名
ethyl 4-[2-(phenylsulfonylamino)ethylsulfinyl]phenoxyacetate;ethyl 2-[4-[2-(benzenesulfonamido)ethylsulfinyl]phenoxy]acetate
ethyl 4-<2-(4-phenylsulfonylamino)ethylsulfinyl>phenoxyacetate化学式
CAS
141267-11-0
化学式
C18H21NO6S2
mdl
——
分子量
411.5
InChiKey
IHNGGMYWBUKAQH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    608.1±65.0 °C(Predicted)
  • 密度:
    1.39±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    27
  • 可旋转键数:
    11
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    126
  • 氢给体数:
    1
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and evaluation of novel sulfonamide derivatives as thromboxane A2 receptor antagonists I
    摘要:
    A series of 4-[2-(arylsulfonylamino)ethylthio]phenoxyacetic acids and related compounds were synthesized. The compounds were tested for their thromboxane A2 (TXA2) receptor antagonizing effects on (15S)-15-hydroxy-11a,9a-(epoxymethano)prosta-5(Z),13(E)-dienoic acid (U-46619)-induced aggregation of rabbit platelet-rich plasma (PRP). Among the compounds synthesized, 3-{4-[2-(arylsulfonylamino)ethylthio]phenyl}propionic acids 26a-e,g showed potent TXA2 receptor antagonist activity. The most potent compound, 3-14-[2-(4-chlorophenylsulfonylamino)ethylthio]phenyl}propionic acid 26c was more than 10-fold more potent in TXA2 receptor antagonizing activity (IC50 = 1.1 X 10(-6) M) than sulotroban (BM- 1 3177) on rabbit platelets. Compound 26c was also more than 10-fold more potent in TXA2-inhibitory activity than sulotroban on rat aorta smooth muscle (pA2 7.7).
    DOI:
    10.1016/0223-5234(94)90036-1
  • 作为产物:
    参考文献:
    名称:
    Synthesis and evaluation of novel sulfonamide derivatives as thromboxane A2 receptor antagonists I
    摘要:
    A series of 4-[2-(arylsulfonylamino)ethylthio]phenoxyacetic acids and related compounds were synthesized. The compounds were tested for their thromboxane A2 (TXA2) receptor antagonizing effects on (15S)-15-hydroxy-11a,9a-(epoxymethano)prosta-5(Z),13(E)-dienoic acid (U-46619)-induced aggregation of rabbit platelet-rich plasma (PRP). Among the compounds synthesized, 3-{4-[2-(arylsulfonylamino)ethylthio]phenyl}propionic acids 26a-e,g showed potent TXA2 receptor antagonist activity. The most potent compound, 3-14-[2-(4-chlorophenylsulfonylamino)ethylthio]phenyl}propionic acid 26c was more than 10-fold more potent in TXA2 receptor antagonizing activity (IC50 = 1.1 X 10(-6) M) than sulotroban (BM- 1 3177) on rabbit platelets. Compound 26c was also more than 10-fold more potent in TXA2-inhibitory activity than sulotroban on rat aorta smooth muscle (pA2 7.7).
    DOI:
    10.1016/0223-5234(94)90036-1
点击查看最新优质反应信息

文献信息

  • Sulfonamide derivatives
    申请人:Taisho Pharmaceutical Co., Ltd.
    公开号:US05189211A1
    公开(公告)日:1993-02-23
    A sulfonamide derivative represented by the Formula: ##STR1## wherein A, B, X, Y, R, m and n are as defined in the specification, and a salt thereof have thromboxane A.sub.2 antagonism, therefore they are useful, for example, as blood platelet aggregation inhibiting agents.
    一种磺酰胺衍生物,其化学式表示为:##STR1## 其中A、B、X、Y、R、m和n如规范中定义的那样,并且其盐具有血栓素A.sub.2拮抗作用,因此它们可用作例如血小板聚集抑制剂。
  • Glutamic acid receptor agonist
    申请人:Nippon Suisan Kaisha, Ltd.
    公开号:US05955505A1
    公开(公告)日:1999-09-21
    A method comprising administering a sulfonamide derivative to a patient requiring activation of glutamate receptors, the sulfonamide derivative represented by the formula ##STR1## wherein A is a napthyl group, a pyridyl group, a phenyl group, a phenyl group substituted by 1 to 5 members selected from the group consisting of a halogen atom, an alkyl group having 1 to 40 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a nitro group, and an acetamido group, or an alkyl group having 1 to 20 carbon atoms; B is an alkylene group having 1 to 3 carbon atoms, a group of --OCH.sub.2 -- or a group of --CH.dbd.CH--; X and Y are the same or different, and are each a hydrogen atom or a fluorine atom; R is a carboxy group, an alkoxycarbonyl group having 2 to 5 carbon atoms, a hydroxymethyl group or a group of ##STR2## wherein R.sub.1 is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; and R.sub.2 is a hydrogen atom, a hydroxyl group, an alkyl group having 1 to 3 carbon atoms, a carboxymethyl group or an alkoxycarbonylmethyl group having 3 to 6 carbon atoms; m is an integer from 0 to 2; and n is an integer from 0 to 3, or an pharmaceutically acceptable salt thereof, as an effective ingredient. The agonist is efficacious in the medical treatment of nerve degenerative disorders.
    一种方法,包括向需要激活谷氨酸受体的患者给予磺酰胺衍生物,所述磺酰胺衍生物由以下式子表示:##STR1##其中,A是萘基、吡啶基、苯基、被1到5个选自卤素原子、具有1到40个碳原子的烷基、具有1到4个碳原子的烷氧基、硝基和乙酰胺基的基团取代的苯基或具有1到20个碳原子的烷基;B是具有1到3个碳原子的烷基、--OCH.sub.2--基团或--CH.dbd.CH--基团;X和Y相同或不同,是氢原子或氟原子;R是羧基、具有2到5个碳原子的烷氧羰基基团、羟甲基基团或##STR2##其中,R.sub.1是氢原子或具有1到3个碳原子的烷基;R.sub.2是氢原子、羟基、具有1到3个碳原子的烷基、羧甲基基团或具有3到6个碳原子的烷氧羰基甲基基团;m是0到2的整数;n是0到3的整数,或其药学上可接受的盐,作为有效成分。该激动剂在神经退行性疾病的医疗治疗中有效。
  • GLUTAMIC ACID RECEPTOR AGONIST
    申请人:NIPPON SUISAN KAISHA, LTD.
    公开号:EP0811375A1
    公开(公告)日:1997-12-10
    A glutamic acid receptor agonist which comprises as the active ingredient sulfonamide derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof wherein A represents naphthyl, pyridyl, phenyl optionally having 1 to 5 substituents selected from the group consisting of halogeno, C1-4 alkyl, C1-4 alkoxy, nitro and acetamido, or C¿1-20 alkyl; B represents C¿1-3 alkylene, -OCH2- or -CH=CH-; X and Y are the same or different and each represents hydrogen or fluoro; R represents carboxy, C2-5 alkoxycarbonyl, hydroxymethyl or (a) (wherein R1 represents hydrogen or C1-3 alkyl; and R2¿ represents hydrogen, hydroxy, C1-3 alkyl, carboxymethyl or C¿3-6 alkoxycarbonyl); m represents an integer of 0 to 2 and n represents an integer of 0 to 3. The agonist is efficatious in the prevention and treatment of nerve degeneration in morbid conditions.
    一种谷氨酸受体激动剂,其活性成分包括通式(I)所代表的磺酰胺衍生物或其药学上可接受的盐 其中A代表萘基、吡啶基、苯基,可任选具有1至5个取代基,这些取代基选自由卤素、C1-4烷基、C1-4烷氧基、硝基和乙酰氨基或C¿1-20烷基组成的组;B代表C¿1-3亚烷基、-OCH2-或-CH=CH-;X和Y相同或不同,各自代表氢或氟;R代表羧基、C2-5烷氧基羰基、羟甲基或(a)(其中R1代表氢或C1-3烷基;R2¿代表氢、羟基、C1-3烷基、羧甲基或C¿3-6烷氧基羰基);m代表0至2的整数,n代表0至3的整数。该激动剂对预防和治疗病态情况下的神经变性具有疗效。
  • US5189211A
    申请人:——
    公开号:US5189211A
    公开(公告)日:1993-02-23
  • US5955505A
    申请人:——
    公开号:US5955505A
    公开(公告)日:1999-09-21
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐